Headlines about Madrigal Pharmaceuticals (NASDAQ:MDGL) have trended somewhat negative this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Madrigal Pharmaceuticals earned a news sentiment score of -0.07 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.4452094233042 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Zacks Investment Research Upgrades Madrigal Pharmaceuticals (MDGL) to Buy (americanbankingnews.com)
- Madrigal Pharmaceuticals (MDGL) PT Raised to $156.00 (americanbankingnews.com)
- Madrigal Pharmaceuticals (MDGL) Coverage Initiated at Goldman Sachs (americanbankingnews.com)
- Goldman Sachs: Madrigal Pharma Has Blockbuster Potential In Liver, Cholesterol Treatments (finance.yahoo.com)
A number of equities research analysts recently issued reports on the stock. HC Wainwright assumed coverage on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 29th. They set a “buy” rating and a $54.00 price target on the stock. Roth Capital set a $82.00 price target on shares of Madrigal Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 30th. JMP Securities upped their price target on shares of Madrigal Pharmaceuticals from $63.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday, December 6th. Evercore ISI upped their price target on shares of Madrigal Pharmaceuticals from $65.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, December 7th. Finally, Zacks Investment Research raised shares of Madrigal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a research note on Wednesday, December 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $160.33.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.03. equities research analysts forecast that Madrigal Pharmaceuticals will post -3.42 earnings per share for the current fiscal year.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.